Bisphosphonate Use Is Not Associated With Tuberculosis Risk Among Patients With Osteoporosis: A Nationwide Cohort Study.
National Health Insurance Research Database
bisphosphonates
osteoporosis
propensity score
tuberculosis
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
07
03
2022
accepted:
23
05
2022
pubmed:
2
6
2022
medline:
19
10
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Bisphosphonates are considered an effective inhibitor of glutamine synthetase and thus can be used for treating tuberculosis (TB). However, its clinical benefit in TB remains unknown. We conducted a population-based cohort study by using the Taiwan National Health Insurance Research Database and TB databases of the Taiwan Centers for Disease Control. Patients with osteoporosis and a history of bone fracture from 2007 to 2014 were identified. Among them, bisphosphonate users and propensity score-matched nonusers were selected. A stratified multivariable Cox proportional hazard regression model was employed to investigate the independent predictors of TB. Among 218 908 patients with osteoporosis and bone fracture, 46 842 bisphosphonate users and 46 842 propensity score-matched nonusers were selected. Within the 2-year follow-up, 723 patients-348 in the user group and 375 in the nonuser group-developed TB. Bisphosphonate use was not an independent predictor of TB in the multivariable Cox proportional hazard model (adjusted hazard ratio, 0.86; 95%CI, 0.71-1.04); however, male sex, older age, being bedridden, and steroid use were independent risk factors. The real-world data revealed that bisphosphonate use did not protect patients with osteoporosis against TB.
Substances chimiques
Diphosphonates
0
Steroids
0
Glutamate-Ammonia Ligase
EC 6.3.1.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1412-1418Informations de copyright
© 2022, The American College of Clinical Pharmacology.
Références
Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.
World Health Organization. Global Tuberculosis Report. World Health Organization; 2020.
World Health Organization. Resolution WHA67/11: Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015. World Health Organization; 2014.
Zumla A, Maeurer M. Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs. J Infect Dis. 2012;205(suppl 2):S335-S339.
Kosikowska P, Bochno M, Macegoniuk K, Forlani G, Kafarski P, Berlicki L. Bisphosphonic acids as effective inhibitors of Mycobacterium tuberculosis glutamine synthetase. J Enzyme Inhib Med Chem. 2016;31(6):931-938.
Harth G, Clemens DL, Horwitz MA. Glutamine synthetase of Mycobacterium tuberculosis: extracellular release and characterization of its enzymatic activity. Proc Natl Acad Sci USA. 1994;91(20):9342-9346.
Harth G, Horwitz MA. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets. J Exp Med. 1999;189(9):1425-1436.
Harth G, Maslesa-Galić S, Tullius MV, Horwitz MA. All four Mycobacterium tuberculosis glnA genes encode glutamine synthetase activities but only GlnA1 is abundantly expressed and essential for bacterial homeostasis. Mol Microbiol. 2005;58(4):1157-1172.
Harth G, Horwitz MA. Inhibition of Mycobacterium tuberculosis glutamine synthetase as a novel antibiotic strategy against tuberculosis: demonstration of efficacy in vivo. Infect Immun. 2003;71(1):456-464.
Mowbray SL, Kathiravan MK, Pandey AA, Odell LR. Inhibition of glutamine synthetase: a potential drug target in Mycobacterium tuberculosis. Molecules. 2014;19(9):13161-13176.
Kumari M, Subbarao N. Virtual screening to identify novel potential inhibitors for glutamine synthetase of Mycobacterium tuberculosis. J Biomol Struct Dyn. 2020;38(17):5062-5080.
Lee MC, Lee CH, Chang LY, et al. Association of metformin use with end-stage renal disease in patients with type 2 diabetes mellitus: a nationwide cohort study under the pay-for-performance program. J Clin Pharmacol. 2019;59(11):1443-1452.
Lee MC, Chiang CY, Lee CH, et al. Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: a nationwide cohort study with validated diagnostic criteria. PLoS ONE. 2018;13(10):e0205807.
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018;40:e2018062.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic Proc. 2008;83(9):1032-1045.
Chmielewska E, Kafarski P. Physiologic activity of bisphosphonates - recent advances. Open Pharm Sci J. 2016;3:56-73.
Taiwan Tuberculosis Control Report 2017. Centers for Disease Control, Ministry of Health and Welfare, R.O.C. (Taiwan). 2018. Available from: https://www.cdc.gov.tw/InfectionReport/Info/upxJr9t9iKeSbo_Wpacpuw?infoId=XYpBd4ytPca4Lq-Pq_obPA. Accessed March 18, 2020.
Global Tuberculosis Report 2019. World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://who.int/publications/i/item/9789241565714. Accessed March 2020.
Yen YF, Hu HY, Lee YL, et al. Sexual inequality in incident tuberculosis: a cohort study in Taiwan. BMJ Open. 2018;8(2):e020142.
Marçôa R, Ribeiro AI, Zão I, Duarte R. Tuberculosis and gender - factors influencing the risk of tuberculosis among men and women by age group. Pulmonology. 2018;24(3):199-202.
Aemro A, Jember A, Anlay DZ. Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos Referral Hospital, Northwest Ethiopia: retrospective follow-up study. BMC Infect Dis. 2020;20(1):245.
Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55(1):19-26.
Lee MR, Lee MC, Chang CH, et al. Use of antiplatelet agents and survival of tuberculosis patients: a population-based cohort study. J Clin Med. 2019;8(7):923. http://doi.org/10.3390/jcm8070923
Su VY, Pan SW, Yen YF, Feng JY, Su WJ, Chen YM. Statin use and impact on tuberculosis risk. Expert Rev Anti Infect Ther. 2021;19(9):1093-1098.